BioCryst (BCRX) Pharmaceuticals announced that Dr. Helen Thackray, chief research and development officer, CRDO, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves
- BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating
- BioCryst Pharmaceuticals Reports Record Q2 2025 Results